Quarterly report [Sections 13 or 15(d)]

Acquisitions - Pulmokine Acquisition (Details)

v3.26.1
Acquisitions - Pulmokine Acquisition (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
Nov. 30, 2024
Mar. 31, 2026
Mar. 31, 2025
Asset Acquisition      
Amortization of intangible assets   $ 892 $ 544
Revenue from contracts with customers     4,000
Pulmokine      
Asset Acquisition      
Closing cash payment $ 20,500    
Estimated useful life 12 years    
Amortization of intangible assets   500 500
Impairment of intangible asset   0  
Contract assets under Moderna collaboration   0  
Contract liabilities under Moderna collaboration   0  
Revenue from contracts with customers   $ 0 $ 0